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Abstract
Background: Gestational Diabetes Mellitus (GDM), maternal obesity and pregnancy weight gain are associated
with an increased risk of developing Preeclampsia (PE). The aim of this study was to examine the predictors of PE
in women commencing pharmacotherapy for GDM in the Metformin in Gestational diabetes trial.
Methods: Descriptive and logistic regression analyses examined the relationship between maternal enrolment
characteristics and later development of PE.
Results: 46 (6.3%) of 703 women developed PE. At enrolment ((30 (SD3.2) weeks gestation), women who later
developed PE had higher HbA1c (6.14% (95%CI 5.84, 6.45) vs. 5.73% (95%CI 5.67, 5.78), P=0.003), fasting
triglycerides (2.93 mmol/L (95%CI 2.57, 3.29) vs. 2.55mmol/L (95%CI 2.47, 2.62), P=0.03) and blood pressure.
Their infants were born 9 days earlier (P<0.001) but were otherwise not different. In univariate analysis, the
strongest positive predictors for PE were Polynesian ethnicity (OR 2.75 (95%CI 1.48, 5.09), P=0.001), personal or
family history of PE (OR 2.65 (95%CI 1.36, 5.16), P=0.004), maternal HbA1c (OR 1.96 (95%CI 1.35, 2.89),
P<0.001), triglycerides (OR 1.45 (95%CI 1.07,1.97), P=0.002), and weight gain from early pregnancy (OR 1.09
(95%CI 1.03,1.17), P=0.01). HDL-C was a negative predictor of PE (OR 0.29 (95%CI 0.09, 0.94), P=0.04). Following
adjustment for Polynesian ethnicity and personal or family history of PE, and when further adjusted for HbA1c or
early pregnancy BMI, these variables remained significant.
Conclusion: Treatment allocation and BMI were not associated with risk of PE. Personal or family history of PE,
Polynesian ethnicity, degree of hyperglycemia, maternal triglycerides and weight gain prior to treatment signal
increased risk of subsequent PE in women needing pharmacotherapy for GDM.
Keywords: Gestational diabetes mellitus; Preeclampsia; Glucose;
Lipids; Metformin; Pregnancy; Ethnicity
Background
Preeclampsia (PE) is associated with increased maternal and infant
morbidity and mortality [1] and is often defined for research purposes
by the presence of maternal hypertension and proteinuria with onset
after 20 weeks gestation. It is associated with the development of short
term morbidity, such as eclampsia, placental abruption and
intrauterine growth restriction, and long term issues, including a
higher rate of maternal hypertension, cardiac and renal disease later in
life and long term hypertension for the infant [2-4].
Increased risk of PE has previously been related to maternal
hyperglycemia, maternal obesity, and gestational weight gain amongst
other factors. Recent studies suggest a relationship of PE frequency
with ethnicity and in particular that Maori women may be at higher
risk of PE [5-11].
The Metformin in Gestational diabetes (MiG) Trial was a
randomized controlled trial of metformin compared with insulin for
the treatment of women requiring pharmacotherapy for Gestational
Diabetes (GDM) [12]. The rate of PE did not differ between treatment
arms (Metformin 5.5%, Insulin 7.0%, P=0.40) and the participants
were extremely well characterized clinically and biochemically. This
offers the opportunity to examine the associations of PE in a
multiethnic group of women, including a large proportion of women
from Maori and Pacific Islander background.
The aim of this study was to assess what may predict the later
development of PE in women commencing pharmacotherapy with
insulin or metformin for the treatment of GDM.
Methods
The trial was approved by institutional review boards at each
participating site, and all subjects gave written informed consent.
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Ethnicity was self-defined. In this analysis, Polynesian ethnicity
combines women of Maori and Pacific Islander background.
PE and Gestational Hypertension (GH) were defined by the Society
of Obstetric Medicine of Australia and New Zealand guidelines [13].
Of 733 women in who completed the original MiG trial, thirty (4.1%)
women had GH alone and were excluded from the analysis, giving 703
women in the current analyses. Data were collected of a personal
history of Chronic Hypertension (CH), aspirin use and a personal or
family history (in first or second degree relatives) of PE at their initial
visit [12].
Laboratory analyses
Blood samples were collected from each woman after an overnight
fast at enrolment (20-33 weeks gestation), and at 36 weeks gestation.
Maternal spot urine Albumin: Creatine Ratio (ACR) was measured at
enrolment. Cord blood was collected after ligation of the umbilical
cord postpartum. All blood was collected in EDTA and plain tubes and
processed within 10 minutes of collection or stored on ice for
processing within 90 minutes. Aliquots were stored at −80°C for
subsequent analysis. Plasma variables were measured as previously
described [12].
Statistical analysis
Descriptive statistics include mean and 95% confidence interval
(95%CI) for continuous variables and numbers and percentages for
categorical variables. Statistical analysis was performed using Kruskal-
Wallis Test for continuous variables, and Pearson’s Chi-Squared test
for categorical variables. Correlation analyses were performed using
Spearman’s Correlation coefficient. Logistic regression analyses were
performed for the outcome of PE diagnosis using only predictor
variables measured at enrolment to the study. For each predictor,
univariable relations were analysed, then Model I - the univariable
relation adjusted for Polynesian ethnicity, and personal or family
history of PE (1=yes). Model II included the variables in Model I as
well as HbA1c at enrolment. Model III included the variables in Model
I as well as Body Mass Index (BMI - kg/m2) in early pregnancy. Due to
the lower numbers of women having data on HDL, LDL and total
cholesterol, Model I was adjusted for Polynesian ethnicity (1=yes).
Model II was adjusted for HbA1c at enrolment. Model III was adjusted
for BMI in early pregnancy.
Backward regression modelling was undertaken, using the
likelihood ratio, with the probability of the score statistic for entry of
0.05, and removal of 0.1. In this model, enrolment HbA1c,
triglycerides, early pregnancy BMI, Polynesian ethnicity, nulliparity,
personal or family history of PE, and maternal age were included in
the initial model. HDL-C, despite being significantly associated with
PE in the other models, was not included in the stepwise regression
analysis, given that fewer women had this variable available (Table 1).
Normotensive PE P
Maternal characteristics at enrolment
Maternal Age (years) 32.9 (32.5-33.3) 31.44 (29.58-33.29) 0.12
Nulliparous n (%) 204 (31.3) [652] 20 (43.5) 0.09
Metformin treatment 330 (50.2) 20 (43.5) 0.78
Caucasian n (%) 319 (48.6) 18 (39.1) 0.02
Indian n (%) 89 (13.5) 4 (8.7)
Polynesian n (%) 134 (20.4) 19 (41.3)
Asian n (%) 86 (13.1) 4 (8.7)
Other n (%) 29 (4.4) 1 (2.2)
Tertiary education n (%) 292 (44.9) 17 (37.0) 0.30
Aspirin use in pregnancy 40 (6.1) 3 (6.5) 0.91
Personal history of chronic hypertension 48 (7.3) 9 (19.6) 0.003
Previous preeclampsia * 43 (9.2) [448] 8(30.8) [26] <0.001
Family history of preeclampsia 58 (8.8) 8 (17.4) 0.05
Personal or family history of preeclampsia 93 (14.2) 14 (30.4) 0.003
Smoking in pregnancy n (%) 106 (16.1) 9 (19.6) 0.54
Gestational age at enrolment (weeks) 30.1 (29.8-30.3) 30.40 (29.62-31.18) 0.96
BMI in early pregnancy (kg/m2) 31.89 (31.22-32.56) [535] 33.49 (30.74-36.23) [29] 0.22
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Change in maternal weight from early pregnancy to
randomization (kg)
6.50 (6.05-6.95) [533] 9.44 (6.53-12.37) [29] 0.10
Systolic BP at enrolment (mmHg) 112.0 (111.0-113.0) [641] 124.9 (121.0-128.7) <0.001
Diastolic BP at enrolment (mmHg) 67.6 (66.9-68.3) 77.0 (74.4-79.7) <0.001
Fasting glucose (mmol/L) 5.20 (5.12-5.28) [558] 5.76 (5.21-6.31) [35] 0.09
HbA1c (%) 5.73 (5.67-5.78) [598] 6.14 (5.84-6.45) [39] 0.003
Fasting triglycerides (mmol/L) 2.55 (2.47-2.62) [550] 2.93 (2.57-3.29) [37] 0.03
Fasting cholesterol (mmol/L) 6.07 (5.91-6.24) [342] 5.82 (5.22-6.42) [22] 0.37
Fasting HDL-cholesterol (mmol/L) 1.72 (1.67-1.76) [350] 1.53 (1.38-1.68) [22] 0.08
Fasting LDL-cholesterol (mmol/L) 3.21 (3.06-3.36) [342] 2.87 (2.38-3.36) [22] 0.25
Infant Characteristics
Gestational age at delivery (days) 269.3 (268.6-270.0) 261.6 (258.4-264.8) <0.001
Born less than 37 weeks n (%) 55 (8.4) 15 (32.6) <0.001
Female n (%) 322 (49.0) 20 (43.5) 0.47
Adjusted birth weight centile (%) *** 54.10 (51.76-56.44) 52.44 (42.14-62.74) 0.82
<10th centile n (%) 68 (10.4) 8 (17.4) 0.14
APGAR 1 min ** 9 9 0.44
APGAR 5 min ** 9 10 0.37
Cord glucose (mmol/L) 4.73 (4.59-4.88) [417] 4.23 (3.69-4.77) [15] 0.23
Cord triglycerides (mmol/L) 0.41 (0.39-0.43) [419] 0.52 (0.36-0.68) [15] 0.11
Table 1: Comparison of demographic and pregnancy variables at enrolment between normotensive women and those with preeclampsia. Data is
mean and 95% CI [n], and n= 657 for normotensive, and 46 for PE except where indicated, *in non-nulliparous women, **median, *** Adjusted
birth weight centile [35].
We also undertook additional analyses comparing the clinical
characteristics of three groups: normotensive, GH, PE. A logistic
regression was performed for the outcome of PE or GH. As there were
a greater number of outcomes, the models were able to accommodate
a higher number of variables. For each association, univariable
relations were analyzed, then Model I with each variable adjusted for
nulliparity (yes=1), Polynesian ethnicity (1= yes), and personal or
family history of PE (1=yes). Model II was each variable adjusted for
the variables in Model I as well as for HbA1c at enrolment. Model III
was each variable adjusted for the variables in Model I as well as BMI
in early pregnancy.
Results
In the 703 women, who were enrolled at an average of 30 weeks
gestation, 46 (6.5%) were diagnosed subsequently with PE; 6 (13.0%)
delivered prior to 36 weeks gestation and 67.4% delivered after 37
weeks gestation. Maternal and infant characteristics of women who
did not develop hypertensive complications compared with those who
developed PE are seen in Table 1. At enrolment, women who went on
to develop PE had higher systolic and diastolic blood pressure, higher
HbA1c, and higher triglycerides. Ethnicity was different between the
groups but maternal BMI, weight gain prior to randomization and
smoking were not. The babies of women who developed PE were born
on average 8 days earlier (P<0.001) but were otherwise not different.
There were no differences in cord blood metabolic parameters.
The strongest univariate positive predictors of the development of
PE at commencement of pharmacotherapy were Polynesian ethnicity
(OR 2.75 (95%CI 1.48,5.09), P=0.001), personal or family history of PE
(OR 2.65 (95%CI 1.36, 5.16), P=0.004), HbA1c (OR 1.96 (95%CI 1.35,
2.89), P<0.001), fasting glucose (OR 1.48 (95%CI 1.15, 1.91), P=0.002),
triglycerides (OR 1.45 (95%CI 1.07, 1.97), P=0.02), and weight gain
from early pregnancy (OR 1.09 (95%CI 1.03, 1.17), P=0.01) (Table 2).
Increasing maternal HDL-C was associated with lower odds of
developing PE (OR 0.29 (95%CI 0.09, 0.94), P=0.04). No other ethnic
group (Caucasian, Indian, Asian) was related to a diagnosis of PE (not
shown).
Polynesian women had a higher early pregnancy BMI (37.2 kg/m2,
95%CI 35.8, 38.6) than women of other ethnic groups ((Caucasian 33.3
kg/m2 (95%CI 32.4, 34.3), Indian 26.8 kg/m2 (95%CI 25.7, 27.8), Asian
(25.9 kg/m2 (95%CI 25.0, 26.8), other 32.6 kg/m2 (29.9, 35.4),
P<0.001). They also had higher enrolment fasting glucose (P<0.001)
and HbA1c ((Polynesian 6.17% (95%CI 6.04, 6.30), Caucasian 5.52%
(95%CI 5.46, 5.58), Indian 5.89% (95%CI 5.75, 6.03), Asian 5.80%
(95%CI 5.66, 5.94), other 6.02% (95%CI 5.69, 6.34), P<0.001)).
Triglycerides did not differ between ethnic groups at enrolment
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(P=0.29). There was a trend to higher enrolment urinary albumin:
creatinine ratio (ACR) in Polynesian women (mean ACR 4.00 mg/
mmol (95%CI 1.90, 6.20), compared with the other ethnic groups
(P=0.20) (Caucasian mean ACR 1.72 mg/mmol (95%CI 1.03, 2.40),
Indian 1.40 mg/mmol (0.72, 2.08), Asian 2.05 mg/mmol (0.39, 3.71),
Other 0.95 mg/mmol (0.62, 1.23)). Polynesian women had a lower rate
of CH than Caucasian women (Polynesian 11 (7.2%), Caucasian 39
(11.6%), Indian 6 (6.5%), Asian 0, and Other 1 (3.3%) P=0.01). There
were no ethnic differences in rates of aspirin use (p=0.07), or personal










OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Maternal Age (years) 0.95 (0.90-1.01) 0.07 0.96 (0.91-1.02) 0.15 0.97 (0.91-1.03) 0.29 0.97 (0.93-1.07) 0.92
Personal or family history
PE 2.65 (1.36-5.16) 0.004 2.80 (1.43-5.51) 0.003 2.66 (1.28-5.57) 0.01 1.77 (0.73-4.33) 0.21
Polynesian Ethnicity 2.75 (1.48-5.09) 0.001 2.87 (1.54-5.35) 0.001 2.03 (0.98-4.22) 0.06 2.93 (1.26-6.85) 0.01
Nulliparity 1.69 (0.92-3.10) 0.09 2.66 (1.37-5.20) 0.004 2.61 (1.25-5.42) 0.01 2.35 (1.04-5.30) 0.04
Smoking 1.26 (0.59-2.70) 0.54 1.19 (0.55-2.58) 0.66 1.35 (0.58-3.11) 0.49 1.27 (0.49-3.26) 0.62
Metformin Therapy 0.76 (0.42-1.39) 0.38 0.78 (0.42-1.44) 0.42 0.93 (0.48-1.81) 0.83 0.87 (0.41-1.86) 0.72
Maternal BMI in early
pregnancy (kg/m2) 1.03 (0.98-1.07) 0.29 1.00 (0.95-1.06) 0.9 1.01 (0.96-1.07) 0.67 - -
Weight gain from early
pregnancy to enrolment (kg) 1.09 (1.03-1.17) 0.01 1.08 (1.02-1.15) 0.02 1.08 (1.00-1.15) 0.04 - -
HbA1c (%) 1.96 (1.35-2.89) <0.001 1.48 (1.08-2.04) 0.02 - - 1.74 (1.05-2.87) 0.03
Fasting glucose (mmol/L) 1.48 (1.15-1.91) 0.002 1.71 (1.13-2.58) 0.01 - - 1.60 (1.13-2.27) 0.01
Fasting triglycerides
(mmol/L) 1.45 (1.07-1.97) 0.02 1.31 (1.00-1.72) 0.05 1.40 (1.01-1.95) 0.05 1.66 (1.14-2.42) 0.01
Fasting cholesterol
(mmol/L)* 0.89 (0.66-1.20) 0.44 0.97 (0.70-1.33) 0.83 0.95 (0.69-1.30) 0.73 0.94 (068-1.31) 0.72
Fasting HDL-cholesterol
(mmol/L) * 0.29 (0.09-0.94) 0.04 0.26 (0.08-0.86) 0.03 0.30 (0.09-0.94) 0.04 0.29 (0.08-1.09) 0.07
Fasting LDL-cholesterol
(mmol/L) * 0.82 (0.57-1.17) 0.27 0.89 (0.62-1.28) 0.54 0.89 (0.61-1.30) 0.55 0.83 (0.55 - 1.24) 0.36
Table 2: Logistic regression for the outcome of preeclampsia diagnosis using variables at enrolment in study (i.e. the point women were started
on pharmacotherapy for GDM), showing Univariate then adjusted models. These regressions include PE and normotensive women, but did not
include those women with gestational hypertension in the cohort. For each association, univariable relations are presented in the first column.
Model I is each variable adjusted for Polynesian ethnicity (1=yes) and personal or family history of preeclampsia (1=yes). Model II is each
variable adjusted for the variables in Model I as well as HbA1c at enrolment. Model III is each variable adjusted for the variables in Model I as
well as BMI in early pregnancy. *Due to the lower numbers in these variables, Model I is each variable adjusted for Polynesian ethnicity (1=yes).
Model II is adjusted for HbA1c at enrolment. Model III is adjusted for BMI in early pregnancy.
Rates of smoking during pregnancy also differed between
ethnicities: 22.6% Caucasian, 17.6% Polynesian, 3.2% Indian, 5.6%
Asian and 13.3% women of Other ethnicity were smoking during
pregnancy (P<0.001). Smoking during pregnancy was not a predictor
in univariate analysis (OR 1.26 (95%CI 0.59, 2.70), P=0.54) and
remained non-significant under all models.
The adjusted models are also shown in table 2. Both HbA1c and
fasting glucose at enrolment were significant predictors. However,
they were moderately correlated (Spearman’s rho=0.47, P=0.001) and
so only HbA1c has been adjusted for in the regression models and
included in the backward regression. The associations of maternal
HbA1c, fasting glucose, weight gain from early pregnancy and
triglycerides at enrolment were unchanged under the adjusted models.
The relationship between lower maternal HDL-C and PE remained
robust, even after adjustment for Polynesian ethnicity, HbA1c or early
pregnancy BMI.
While the mean gestation of enrolment in the MiG trial was 30
weeks, randomization was stratified by gestation 20-27 weeks and
28-33 weeks, in case duration of treatment influenced outcomes
differently between treatment arms. There were 135 women
randomized between 20-27 weeks, of which 128 are included in this
analysis (after excluding 7 women with GH). In this group, 7/128
(5.4%) developed PE vs. 39/575 (6.8%) of those randomized after 27
weeks (P=0.59). Treatment duration (as measured by gestation at
enrolment in the study) was not a predictor for PE, either as a
continuous variable which showed no relation to the outcome of PE
(OR 1.03 (95%CI 0.94, 1.14), P=0.52) or as a categorical variable
assessing those enrolled prior to 28 weeks gestation (OR 0.78 (95%CI
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0.35, 1.82), P=0.59). An examination of treatment allocation showed
that 20/330 (6.1%) of women allocated metformin and 26/327 (7.8%)
of women allocated insulin developed PE (P=0.38). Of those who were
randomized early, 1/65 (1.5%) of women allocated metformin and
6/63 (9.5%) of women allocated insulin developed PE (P=0.05).
However, there was no association of PE with treatment allocation
under any of the regression models.
The backward logistic regression analysis for the outcome of PE
found a combination of HbA1c (OR 1.80 (95%CI 1.06, 3.04), P=0.03),
triglycerides (OR 1.58 (95%CI 1.08, 2.32), P=0.02) and Polynesian
ethnicity (OR 3.17 (95%CI 1.20, 8.36), P=0.02) was the most predictive
of the development of PE.
We also examined differences between normotensive women, those
with GH, and those with PE (Supplementary Table 1). A logistic
regression was performed for the outcome of PE or GH. As there were
a greater number of outcomes, the models were able to accommodate
a higher number of variables. There were minor differences in the
results of these logistic regressions, compared with those performed
with PE alone as an outcome. Weight gain and triglycerides became
non-significant in model II, but there was little other variation in the
significance of odds ratios (Supplementary Table 2).
Normotensive (n=657) GH (n=30) PE (n=46) P
Maternal characteristics
Maternal Age (years) 32.9 (32.5-33.3) 31.9 (29.5-34.2) 31.44 (29.58-33.29) 0.24
Nulliparous n (%) 204 (31.3) [652] 13 (43.3) 20 (43.5) 0.10
Metformin Treatment n (%) 330 (50.2) 20 (43.5) 13 (43.3) 0.53
Caucasian n (%) 319 (48.6) 20 (66.7) 18 (39.1) 0.03
Indian n (%) 89 (13.5) 3 (10.0) 4 (8.7)
Polynesian n (%) 134 (20.4) 6 (20.0) 19 (41.3)
Asian n (%) 86 (13.1) 1 (3.3) 4 (8.7)
Other n (%) 29 (4.4) 0 1 (2.2)
Tertiary education n (%) 292 (44.9) 14 (46.7) 17 (37.0) 0.56
Smoking in pregnancy n (%) 106 (16.1) 6 (20.0) 9 (19.6) 0.73
Gestational age at enrolment (weeks) 30.1 (29.8-30.3) 30.5 (29.5-31.5) 30.40 (29.62-31.18) 0.93
BMI at enrolment (kg/m2) 34.60 (34.02-35.18) [656] 36.83 (33.89-39.77) 36.24 (34.02-38.46) 0.14
Maternal weight change from early pregnancy to
enrolment
6.50 (6.05-6.95) [533] 9.45 (6.53-12.37) [29] 9.44 (6.53-12.37) [29] 0.15
Systolic BP (mmHg) 112.0 (111.0-113.0) [641] 122.3 (117.9-126.8) 124.9 (121.0-128.7) <0.001
Diastolic BP (mmHg) 67.6 (66.9-68.3) 73.9 (70.3-77.4) 77.0 (74.4-79.7) <0.001
Fasting glucose (mmol/L) 5.20 (5.12-5.28) [558] 5.40 (4.85-5.96) [25] 5.76 (1.61) [35] 0.20
HbA1c (%) 5.73 (5.67-5.78) [598] 5.86 (5.54-6.18) [27] 6.14 (0.94) [39] 0.01
Fasting triglycerides (mmol/L) 2.55 (2.47-2.62) [550] 2.92 (2.26-3.58) [21] 2.93 (2.57-3.29) [37] 0.05
Fasting cholesterol (mmol/L) 6.07 (5.91-6.24) [342] 5.80 (4.94-6.66) [16] 5.82 (5.22-6.42) [22] 0.34
Fasting HDL-cholesterol (mmol/L) 1.72 (1.67-1.76) [350] 1.66 (1.49-1.83) [16] 1.53 (1.38-1.68) [22] 0.18
Fasting LDL-cholesterol (mmol/L) 3.21 (3.06-3.36) [342] 2.77 (1.93-3.61) [14] 2.87 (2.38-3.36) [22] 0.16
Infant characteristics
Gestational age at delivery (days) 269.3 (268.6-270.0) 270.0 (267.0-273.1) 261.6 (258.4-264.8) <0.001
Female gender n (%) 322 (49.0) 13 (43.3) 20 (43.5) 0.65
Birth weight centile (%) 54.10 (51.76-56.44) 49.25 (39.15-59.35) 52.44 (42.14-62.74) 0.66
<10th centile n (%) 68 (10.4) 2 (6.7) 8 (17.4) 0.25
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APGAR 1 min ** 9 9 9 0.28
APGAR 5 min ** 9 10 10 0.23
Cord glucose (mmol/L) 4.73 (4.59-4.88) [417] 4.33 (3.83-4.83) [19] 4.23 (3.69-4.77) [15] 0.24
Cord triglycerides (mmol/L) 0.41 (0.39-0.43) [419] 0.45 (0.35-0.56) [19] 0.52 (0.36-0.68) [15] 0.16
Supplementary Table 1: Comparison of demographic and pregnancy variables at enrolment between women with normotension, gestational











OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Maternal Age (years) 0.96 (0.91-1.00) 0.05 0.97 (0.92-1.03) 0.3 0.98 (0.92-1.05) 0.54 1.01 (0.94-1.06) 0.88
Nulliparity 1.69 (1.04-2.73) 0.03 2.66 (1.37-5.20) 0.004 2.61 (1.25-5.42) 0.01 2.35 (1.04-5.30) 0.04
Personal or family
history of PE 2.65 (1.36-5.16) 0.004 3.11 (1.56-6.19) 0.001 2.83 (1.34-5.97) 0.006 1.90 (0.77-4.67) 0.16
Polynesian Ethnicity 2.75 (1.48-5.09) 0.001 3.87 (1.97-7.60) <0.001 2.78 (1.27-6.10) 0.01 3.73 (1.53-9.10) 0.004
Smoking 1.28 (0.70-2.33) 0.42 1.12 (0.51-2.43) 0.78 1.29 (0.56-3.00) 0.55 1.19 (0.46-3.08) 0.72
Metformin Therapy 0.76 (0.47-1.23) 0.26 0.78 (0.42-1.44) 0.42 0.94 (0.48-1.84) 0.85 0.87 (0.40-1.86) 0.71
Maternal BMI in early
pregnancy (kg/m2) 1.03 (0.99-1.07) 0.1 1.01 (0.95-1.06) 0.86 1.01 (0.96-1.07) 0.05 - -
Weight gain from early
pregnancy to
enrolment (kg)
1.07 (1.01-1.12) 0.01 1.08 (1.01-1.15) 0.03 1.07 (0.99-1.15) 0.07 - -
HbA1c (%) 1.69 (1.23-2.32) 0.01 1.72 (1.14-2.61) 0.01 - - 1.72 (1.04-2.84) 0.04
Fasting glucose
(mmol/L) 1.36 (1.10-1.69) 0.04 1.30 (0.98-1.71) 0.07 - - 1.56 (1.10-2.20) 0.01
Fasting triglycerides
(mmol/L) 1.43 (1.12-1.83) 0.04 1.43 (1.04-1.98) 0.03 1.36 (0.98-1.89) 0.07 1.60 (1.09-2.33) 0.02
Fasting cholesterol
(mmol/L) 0.89 (0.70-1.12) 0.31 0.97 (0.71-1.34) 0.86 1.00 (0.72-1.38) 0.98 1.02 (0.72-1.45) 0.89
Fasting HDL-
cholesterol (mmol/L) 0.42 (0.17-1.02) 0.06 0.26 (0.08-0.89) 0.03 0.28 (0.08-0.92) 0.04 0.24 (0.06-0.96) 0.04
Fasting LDL-
cholesterol (mmol/L) 0.80 (0.60-1.07) 0.13 0.91 (0.64-1.29) 0.58 0.94 (0.65-1.35) 0.73 0.89 (0.60-1.33) 0.58
Supplementary Table 2: Logistic regression for the outcome of preeclampsia OR gestational hypertension diagnosis using variables at enrolment
in study (ie the point women were started on pharmacotherapy for GDM). Showing Univariate then adjusted models. For each association,
univariable relations are presented in the first column. Model I is each variable adjusted for nulliparity (yes=1), Polynesian ethnicity (1= yes), and
personal or family history of preeclampsia (1=yes). Model II is each variable adjusted for the variables in Model I as well as HbA1c at enrolment.
Model III is each variable adjusted for the variables in Model I as well as BMI in early pregnancy.
Discussion
The current analyses demonstrate that, in women requiring
pharmacotherapy in addition to lifestyle treatment for the treatment of
GDM, a subsequent diagnosis of PE is most strongly predicted by
Polynesian ethnicity, a family or personal history of PE, maternal
glycaemia as reflected in HbA1c, maternal triglycerides and weight
gain from early pregnancy. There was no association of PE with
treatment allocation.
The strength of the current study is that the MiG trial participants
were carefully phenotyped, both metabolically and clinically. There
was no difference in rates of PE between the two treatment arms,
allowing the data to be amalgamated here to analyse the predictors of
PE. The rate of PE we report (6.5%) is similar to but slightly higher
than that seen in a recent population-based study of PE in New
Zealand (5.6%), which included normoglycaemic women as well as
those with pre-gestational diabetes and GDM, but similar to other
studies of GDM. If we include the 30 women with GH, the rate of PE
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in the whole cohort is 6.28% [11]. The majority (67.4%) of the women
with PE in our study delivered after 37 weeks gestation, consistent
with late onset rather than early onset PE. The limitation of the current
study is the low number of PE events, which meant that there was a
limit to the number of variables that could be included in each model
[14]. While it is a post-hoc analysis, the participants in MiG were
extremely well characterised and the MiG trial has offered a unique
opportunity to examine the predictors of PE at a point in time when
women need pharmacotherapy, rather than examining parameters at
diagnosis of GDM or at the end of pregnancy.
Maori ethnicity has previously been associated with higher rates of
PE although a cautionary note about higher serum uric acid
concentrations in this ethnic group has been raised that may make
interpretation difficult [11,14,15]. In the current study, hyperuricemia
was not included in the diagnostic criteria for PE, making it unlikely
that there was a higher rate of PE diagnosis in Polynesian women due
to this. Rates of PE do vary with ethnicity, with previous studies
showing lower rates of PE in Chinese women (1.91%) and African-
American women being at higher risk, while Hispanic women have
similar rates but better clinical outcomes than Caucasian women.
Healthy middle aged Polynesian people have previously been shown to
have higher rates of microalbuminuria and increased urinary protein
forms part of the diagnostic criteria for PE. In the current study,
Polynesian women had marginally higher urine albumin: creatinine
ratio on enrolment but this was not different from the other ethnic
groups [8-10,16]. It could be postulated that higher early pregnancy
BMI and higher fasting glucose at enrolment underlie the influence of
Polynesian ethnicity. However, the strong relationship with Polynesian
ethnicity remained once enrolment HbA1c and early pregnancy BMI
were adjusted for in the modelling. Of course, it is possible that
subsequent glucose control influenced baseline predictors. We have
shown previously that there were no ethnic differences in change of
maternal HbA1c from enrolment to 36 weeks, although HbA1c
remained higher in Polynesian women overall [17]. We have also
shown that glucose control on treatment is a predictor for PE,
particularly post prandial glucose [18]. Whether Polynesian women
have higher postprandial glucose fluctuations before and after
treatment that might relate to their risk, or whether there are other
ethnic specific factors, will require further study.
Maternal obesity is an established predictor of PE in women with
and without GDM [6]. The HAPO (Hyperglycaemia and Averse
Pregnancy Outcome) study analysis reported that the diagnosis of
GDM and maternal obesity were independent but additive risk factors
for PE (GDM: OR 1.74, Obesity: OR 3.91, Both OR 5.98) [19]. An
observational study of 2037 women with GDM found that pre-
pregnancy maternal obesity was much more strongly associated with
pregnancy-induced hypertensive disorders (OR 8.94 (95%CI 4.98,
16.04) than excess gestational weight gain (OR 1.91 (95%CI 1.08, 3.37)
[20]. A relationship with obesity was not observed in the current
study. This may be due to the mean BMI in the MiG cohort being in
the obese range, giving a smaller range in maternal BMI than seen in
other studies, or perhaps to the fact that all women in this cohort
received treatment for GDM, which is known to reduce rates of PE
[21,22].
In the current study, maternal weight gain up to the initiation of
pharmacotherapy was a weak predictor of PE, and maternal early
pregnancy BMI was not associated with PE. The ATLANTIC-DIP
study recently reported that excessive weight gain was associated with
greater odds of developing GH in 543 women with GDM (OR 1.72
(95%CI 1.04, 2.85)) [7]. The association of gestational weight gain and
PE is not universally reported. A prospective cohort of 435 women
with either type 2 diabetes mellitus or GDM showed no association of
gestational weight gain with a composite outcome including PE,
eclampsia, third and fourth degree perineal lacerations, read mission
and wound infection [23]. The weak relationship of maternal weight
gain with PE found in the current study may be due to subsequent
treatment, which may alter later pregnancy weight gain, or to the
influence that weight gain may have on glycaemia in late pregnancy.
Maternal lipid abnormalities are frequently described to precede
and accompany PE. Abnormal lipids, in particular higher triglycerides
and increased lipid peroxidation, are possibly involved in the
pathogenesis of PE through endothelial dysfunction [24-26]. A meta-
analysis of 19 case-control and 3 cohort studies showed a rising risk of
PE with increasing triglycerides, at the time of PE, preceding PE
diagnosis and postpartum [27]. A large retrospective database study of
9911 women found an association between an increase in triglycerides
and a higher risk of PE, but did not find any association between
HDL-C and PE [28]. An observational study of 470 normoglycemic
women showed higher triglycerides, but similar HDL-C, LDL-C and
total cholesterol at 28-32 weeks gestation in women who developed PE
[29]. The positive association of maternal triglycerides and PE we
found in our analyses is in keeping with these studies. This finding is
not universal, with one study examining 184 women with GDM, and
using metabolic measures taken at ~28 weeks gestation and prior to
therapy for GDM, found no difference in maternal lipids (including
triglycerides and HDL-C) and no association with the development of
PE [30]. The negative association of HDL-C and PE we demonstrate
has been reported previously [25,26], but the size of the effect does
need to be interpreted with some caution since fewer women in our
study had HDL-C measured. Metformin treatment has been shown to
be associated with reduced rates of PE, when used from early gestation
in women with polycystic ovarian syndrome [31]. However, this
finding is not universal and other studies in PCOS, type 2 diabetes
mellitus and GDM have not reported the same association [32-34].
The MiG trial, from which these data are taken, did not find any
difference in rates of PE in women allocated to metformin compared
with those allocated to insulin for treatment of GDM, and the two
groups did not differ in glycemic control attained [12]. It is possible
that the reduction in PE rates seen with the use of metformin in some
studies is due to the metabolic control obtained, rather than to
another, more direct, effect of the drug.
Conclusion
In a multiethnic cohort of Australasian women requiring
pharmacotherapy in addition to lifestyle treatment for the treatment of
GDM, development of PE is most strongly predicted by Polynesian
ethnicity, a personal or family history of PE, longer duration of
hyperglycemia and/or higher maternal fasting glucose at diagnosis,
maternal triglycerides as well as weight gain from early pregnancy. The
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